NO308581B1 - Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse - Google Patents

Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse

Info

Publication number
NO308581B1
NO308581B1 NO944210A NO944210A NO308581B1 NO 308581 B1 NO308581 B1 NO 308581B1 NO 944210 A NO944210 A NO 944210A NO 944210 A NO944210 A NO 944210A NO 308581 B1 NO308581 B1 NO 308581B1
Authority
NO
Norway
Prior art keywords
antiprogestin
progestin
implant
medicament
manufacture
Prior art date
Application number
NO944210A
Other languages
English (en)
Norwegian (no)
Other versions
NO944210D0 (no
NO944210L (no
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of NO944210D0 publication Critical patent/NO944210D0/no
Publication of NO944210L publication Critical patent/NO944210L/no
Publication of NO308581B1 publication Critical patent/NO308581B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
NO944210A 1992-05-06 1994-11-04 Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse NO308581B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1992/003574 WO1993021926A1 (en) 1992-05-06 1992-05-06 Minimizing progestin associated breakthrough bleeding
PCT/US1993/004003 WO1993021927A1 (en) 1992-05-06 1993-05-03 Minimizing progestin associated breakthrough bleeding

Publications (3)

Publication Number Publication Date
NO944210D0 NO944210D0 (no) 1994-11-04
NO944210L NO944210L (no) 1994-11-04
NO308581B1 true NO308581B1 (no) 2000-10-02

Family

ID=22231028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944210A NO308581B1 (no) 1992-05-06 1994-11-04 Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse

Country Status (17)

Country Link
EP (1) EP0646008B1 (ja)
JP (1) JP3937240B2 (ja)
KR (1) KR950700745A (ja)
CN (1) CN1073422C (ja)
AT (1) ATE187644T1 (ja)
AU (2) AU1918092A (ja)
CA (1) CA2131911C (ja)
DE (1) DE69327319T2 (ja)
DK (1) DK0646008T3 (ja)
ES (1) ES2142345T3 (ja)
FI (1) FI945207A0 (ja)
GR (1) GR3032797T3 (ja)
NO (1) NO308581B1 (ja)
NZ (1) NZ253405A (ja)
PT (1) PT646008E (ja)
WO (2) WO1993021926A1 (ja)
ZA (1) ZA933153B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
ES2218556T3 (es) * 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
WO1996023503A1 (de) * 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
NZ332894A (en) * 1996-06-25 1999-05-28 Akzo Nobel Nv A regimen containing progestogen and/or estrogen with two or more anti-progestogen dosage units
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
TR200001334T2 (tr) * 1997-11-14 2000-09-21 Akzo Nobel N.V. Progestojen-anti-progestojen rejimleri.
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
SK15502001A3 (sk) * 1999-04-29 2002-03-05 Akzo Nobel N. V. Použitie Org 33245
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935617B (en) * 1992-08-14 1994-03-07 Akzo Nv Antiprogestogen containing contraceptives.

Also Published As

Publication number Publication date
CN1073422C (zh) 2001-10-24
FI945207L (fi) 1994-11-04
DK0646008T3 (da) 2000-05-15
CA2131911C (en) 2005-12-27
ZA933153B (en) 1993-12-06
GR3032797T3 (en) 2000-06-30
NO944210D0 (no) 1994-11-04
AU667729B2 (en) 1996-04-04
ATE187644T1 (de) 2000-01-15
JPH08509456A (ja) 1996-10-08
JP3937240B2 (ja) 2007-06-27
EP0646008B1 (en) 1999-12-15
FI945207A7 (fi) 1994-11-04
AU1918092A (en) 1993-11-29
NZ253405A (en) 1997-06-24
CN1079651A (zh) 1993-12-22
EP0646008A4 (en) 1995-10-11
PT646008E (pt) 2000-04-28
DE69327319T2 (de) 2000-07-13
CA2131911A1 (en) 1993-11-11
DE69327319D1 (de) 2000-01-20
NO944210L (no) 1994-11-04
ES2142345T3 (es) 2000-04-16
FI945207A0 (fi) 1994-11-04
EP0646008A1 (en) 1995-04-05
WO1993021926A1 (en) 1993-11-11
KR950700745A (ko) 1995-02-20
AU4368593A (en) 1993-11-29
WO1993021927A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
NO308581B1 (no) Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse
PL317105A1 (en) Compositions containing dna and p53 damaging agents
BR1100339A (pt) Formulações de aerossol em solução de beclometasona
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
AU3959989A (en) Long lasting contraceptive suppository composition and methods of use
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
GB2100601B (en) An aromatase-inhibitor for use in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia, and pharmaceutical preparations suitable for such a use.
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
EP0350738A3 (de) (S)-Emopamil zur Anwendung bei der Behandlung von Migräne
JPS57181072A (en) Oxaprodine derivative
UA41351C2 (uk) Спосіб контрацепції та набір таблеток
AU7691794A (en) Progesterone-antagonistic and anti-oestrogen compounds for the therapy of leiomyomata uteri
IL85388A (en) Pharmaceutical compositions containing oxoquinazoline derivatives for the treatment of hyperuricaemia
AU541782B2 (en) Nonapeptide and its use for increasing fertility or for contraception
AU7750794A (en) Use of hydroxychloroquine for treatment of graft-versus-host disease
DK0651741T3 (da) NG-Monomethyl-L-arginin-hydrochloridderivater og fremgangsmåde til fremstilling deraf
GR3005231T3 (ja)
IT1255469B (it) Uso della n-acetil-cisteina nella prevenzione e nel trattamento della discinesia tardiva
ATE18994T1 (de) Neue pharmazeutische zusammensetzung.
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
NO168242C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive indansulfonamider, samt forbindelse for anvendelse ved fremstilling derav.
AU8934898A (en) Use of droloxifene for the treatment of prostatic diseases endometriosis and obesity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees